{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:29:58Z","timestamp":1788254998717,"version":"build-2803163510"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    The global HIV response aims for widespread availability of affordable, quality\u2010assured long\u2010acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low\u2010 and middle\u2010income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in Liverpool, United Kingdom, and co\u2010organized by the Long\u2010Acting\/Extended\u2010Release Antiretroviral Resource Program (LEAP) and the Centre of Excellence for Long\u2010acting Therapeutics (CELT). The workshop brought together experts from across disciplines to evaluate the multifaceted challenges and opportunities for faster development and regulatory approval of affordable and accessible generic LA ARVs. Key topics included the application of novel pharmacokinetic end points to reduce study duration, the integration of community preferences into practice\u2010based research in resource\u2010limited settings, intellectual property considerations, formulation and manufacturing complexities that affect cost, scalability and implementation, and the growing role of model\u2010integrated evidence in streamlining bioequivalence assessments. To reach the goal of timely and equitable global access to long\u2010acting medicines, this workshop emphasized the need for strategic public\u2010private engagement to promote data sharing, enhance regulatory efficiencies, and develop robust\n                    <jats:italic>in vitro\u2013in vivo<\/jats:italic>\n                    correlation strategies that meet regulatory guidance for LAI products.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70238","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:00:16Z","timestamp":1771398016000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Accelerating Generic Long\u2010Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-1885","authenticated-orcid":false,"given":"Usman","family":"Arshad","sequence":"first","affiliation":[{"name":"Centre of Excellence for Long\u2010Acting Therapeutics University of Liverpool  Liverpool UK"},{"name":"Department of Pharmacology and Therapeutics University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-3254","authenticated-orcid":false,"given":"Lobna","family":"Gaayeb","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4522-9201","authenticated-orcid":false,"given":"Henry","family":"Pertinez","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Long\u2010Acting Therapeutics University of Liverpool  Liverpool UK"},{"name":"Department of Pharmacology and Therapeutics University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-5712","authenticated-orcid":false,"given":"Rajith K. R.","family":"Rajoli","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Long\u2010Acting Therapeutics University of Liverpool  Liverpool UK"},{"name":"Department of Pharmacology and Therapeutics University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melynda","family":"Watkins","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Nimbolkar","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-7823","authenticated-orcid":false,"given":"Simone","family":"Perazzolo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Pagi","sequence":"additional","affiliation":[{"name":"Uddipak Consultancy  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-8891","authenticated-orcid":false,"given":"Annemarie","family":"Wensing","sequence":"additional","affiliation":[{"name":"Department of Global Health and Bio\u2010ethics, Julius Center for Health Sciences and Primary Care Translational Virology Research Group University Medical Centre Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0967","authenticated-orcid":false,"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2213-1103","authenticated-orcid":false,"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital Foundation Trust and Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-7765","authenticated-orcid":false,"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Physics, Chemistry and Pharmacy University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9312-7083","authenticated-orcid":false,"given":"Zack","family":"Panos","sequence":"additional","affiliation":[{"name":"Children's Investment Fund Foundation  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-8756","authenticated-orcid":false,"given":"Imelda","family":"Mahaka","sequence":"additional","affiliation":[{"name":"Pangaea Zimbabwe AIDS Trust  Harare Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-5171","authenticated-orcid":false,"given":"Francois","family":"Venter","sequence":"additional","affiliation":[{"name":"Wits Ezintsha University of the Witwatersrand Faculty of Health Sciences  Johannesburg South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Kottiri","sequence":"additional","affiliation":[{"name":"Global Health Bureau USAID  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Division of AIDS National Institute of Allergy and Infectious Diseases  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5960-4288","authenticated-orcid":false,"given":"Rodney J. Y.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-9647","authenticated-orcid":false,"given":"Polly","family":"Clayden","sequence":"additional","affiliation":[{"name":"i\u2010Base  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1586-9120","authenticated-orcid":false,"given":"Paul","family":"Domanico","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Struble","sequence":"additional","affiliation":[{"name":"Division of Antivirals Centre for Drug Evaluation and Research, FDA  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7651","authenticated-orcid":false,"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Long\u2010Acting Therapeutics University of Liverpool  Liverpool UK"},{"name":"Department of Pharmacology and Therapeutics University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-5349","authenticated-orcid":false,"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Physiology, Pharmacology &amp; Therapeutics, and International Health Johns Hopkins University  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_2_18_1_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-071724-100739"},{"key":"e_1_2_18_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_18_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_18_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_18_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_18_6_1","unstructured":"U.S. Food and Drug Administration.The voice of the patient: human immunodeficiency virus (HIV) patient\u2010focused drug development and HIV cure research(Silver Spring MD) (2014)."},{"key":"e_1_2_18_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26498"},{"key":"e_1_2_18_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00161-4"},{"key":"e_1_2_18_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac753"},{"key":"e_1_2_18_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2020.1783233"},{"key":"e_1_2_18_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26092"},{"key":"e_1_2_18_12_1","unstructured":"U.S. Food and Drug Administration.Bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014general considerations(2022)."},{"key":"e_1_2_18_13_1","unstructured":"U.S. Food and Drug Administration.Determining whether to Submit an ANDA or a 505 (b)(2) Application(2019)."},{"key":"e_1_2_18_14_1","unstructured":"U.S. Food and Drug Administration.ANDA Submissions \u2010 Content and Format Guidance for Industry(2019)."},{"key":"e_1_2_18_15_1","unstructured":"U.S. Food and Drug Administration.Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application(2021)."},{"key":"e_1_2_18_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/wics.1310"},{"key":"e_1_2_18_17_1","unstructured":"Watkins M.Learnings from LA hormonal contraceptive programs. LEAP workshop on new approaches for bioequivalence assessment and generic approval of long acting\/extended\u2010release (LA\/ER) antiretroviral drugs September 9th. (2024)."},{"key":"e_1_2_18_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30106-5"},{"key":"e_1_2_18_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00898-8"},{"key":"e_1_2_18_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15439"},{"key":"e_1_2_18_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2922"},{"key":"e_1_2_18_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.02.003"},{"key":"e_1_2_18_23_1","unstructured":"U.S. Food and Drug Administration.Controlled correspondence related to generic drug development guidance for industry(2017)."},{"key":"e_1_2_18_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2223961"},{"key":"e_1_2_18_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.928"},{"key":"e_1_2_18_26_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.11.19"},{"key":"e_1_2_18_27_1","unstructured":"U.S. Food and Drug Administration.General Principles model\u2010integrated evidence (MIE) industry meeting pilot between FDA and generic drug applicants(2023)."},{"key":"e_1_2_18_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.02.003"},{"key":"e_1_2_18_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106296"},{"key":"e_1_2_18_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106718"},{"key":"e_1_2_18_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy726"},{"key":"e_1_2_18_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404619"},{"key":"e_1_2_18_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00638-0"},{"key":"e_1_2_18_34_1","unstructured":"U.S. Food and Drug Administration.Guidance for industry: extended release oral dosage forms: development evaluation and application of in\u00a0vitro\/in vivo correlationsRockville: Food and Drug Administration (1997)."},{"key":"e_1_2_18_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.11.021"},{"key":"e_1_2_18_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13118"},{"key":"e_1_2_18_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16006"},{"key":"e_1_2_18_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf319"},{"key":"e_1_2_18_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.10.009"},{"key":"e_1_2_18_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.02.018"},{"key":"e_1_2_18_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.01.016"},{"key":"e_1_2_18_42_1","unstructured":"Gilead Sciences Inc.Yeztugo\u00ae (Lenacapavir) Is now the first and only FDA\u2010approved HIV prevention option offering 6 months of protection<https:\/\/www.gilead.com\/news\/news\u2010details\/2025\/yeztugo\u2010lenacapavir\u2010is\u2010now\u2010the\u2010first\u2010and\u2010only\u2010fda\u2010approved\u2010hiv\u2010prevention\u2010option\u2010offering\u20106\u2010months\u2010of\u2010protection> (2025). Accessed 21 June 2025."},{"key":"e_1_2_18_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26427"},{"key":"e_1_2_18_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00239-X"},{"key":"e_1_2_18_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_2_18_46_1","first-page":"124","article-title":"Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus phase 2\/3 regimen [PESUB22]","volume":"25","author":"Jogiraju V.","year":"2022","journal-title":"J. Int. AIDS Soc."},{"key":"e_1_2_18_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70226"},{"key":"e_1_2_18_48_1","unstructured":"World Health Organization.Guidelines on lenacapavir for HIV prevention and testing strategies for long\u2010acting injectable pre\u2010exposure prophylaxis. (Geneva;2025)."},{"key":"e_1_2_18_49_1","unstructured":"U.S. Food and Drug Administration.Prescribing information for YEZTUGO\u00ae lenacapavir(2025)."},{"key":"e_1_2_18_50_1","unstructured":"U.S. Food and Drug Administration.Prescribing information for SUNLENCA\u00ae lenacapavir(2022)."},{"key":"e_1_2_18_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004142"},{"key":"e_1_2_18_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121840"},{"key":"e_1_2_18_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124634"},{"key":"e_1_2_18_54_1","unstructured":"Flexner C.How long does a BE study need to be for a LAI ARV?LEAP workshop on new approaches for bioequivalence assessment and generic approval of long acting\/extended\u2010release (LA\/ER) antiretroviral drugs September 9th. (2024)."},{"key":"e_1_2_18_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106253"},{"key":"e_1_2_18_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241301883"},{"key":"e_1_2_18_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6"},{"key":"e_1_2_18_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000301"},{"key":"e_1_2_18_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26101"},{"key":"e_1_2_18_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000169"},{"key":"e_1_2_18_61_1","unstructured":"U.S. Food and Drug Administration.Integrated Review. VOCABRIA (cabotegravir) tablets and CABENUVA (cabotegravir extended\u2010release injectable suspension and rilpivirine extended\u2010release injectable suspension)(2019)."},{"key":"e_1_2_18_62_1","first-page":"175","article-title":"Can \u201cequivalence\u201d of a generic cabotegravir LA be inferred from a shortened pharmacokinetic study? [CROI abstract 644]","volume":"33","author":"Pertinez H.","year":"2025","journal-title":"Top. Antivir. Med."},{"key":"e_1_2_18_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16006"},{"key":"e_1_2_18_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.03.041"},{"key":"e_1_2_18_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24014"},{"key":"e_1_2_18_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1694901"},{"key":"e_1_2_18_67_1","unstructured":"Ford S.et al.Cabotegravir and rilpivirine PK following long\u2010acting HIV treatment discontinuation. Abstract presented at: conference on retroviruses and opportunistic infections (CROI) (2020)."},{"key":"e_1_2_18_68_1","unstructured":"Pagi B.IP considerations in development of generic LAIs for LMICs. LEAP workshop on new approaches for bioequivalence assessment and generic approval of long acting\/extended\u2010release (LA\/ER) antiretroviral drugs September 9th. (2024)."},{"key":"e_1_2_18_69_1","unstructured":"Medicines Patent Pool.Long\u2010Acting technologies patents and licences database LAPaL<http:\/\/www.lapal.ch>. Accessed August 13 2025."},{"key":"e_1_2_18_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.105507"},{"key":"e_1_2_18_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040263"},{"key":"e_1_2_18_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2482654"},{"key":"e_1_2_18_73_1","unstructured":"Medicines Patent Pool.Cabotegravir long\u2010acting (LA) for HIV pre\u2010exposure prophylaxis (PrEP) and treatment<https:\/\/medicinespatentpool.org\/licence\u2010post\/cabotegravir\u2010long\u2010acting\u2010la\u2010for\u2010hiv\u2010pre\u2010exposure\u2010prophylaxis\u2010prep>. Accessed January 17 2026."},{"key":"e_1_2_18_74_1","unstructured":"Holm R.How difficult is it to manufacture a LAI formulation?LEAP workshop on new approaches for bioequivalence assessment and generic approval of long acting\/extended\u2010release (LA\/ER) antiretroviral drugsSeptember 9th(2024)."},{"key":"e_1_2_18_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-023-00755-6"},{"key":"e_1_2_18_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097921"},{"key":"e_1_2_18_77_1","first-page":"52","article-title":"HIV and tuberculosis prevention and control in South Africa: an overview","volume":"2","author":"Venter W.","year":"2018","journal-title":"South. Afr. J. Public Health."},{"key":"e_1_2_18_78_1","unstructured":"U.S. Food and Drug Administration.Draft guidance on cabotegravir October 2025(2025)."},{"key":"e_1_2_18_79_1","unstructured":"U.S. Food and Drug Administration.Draft guidance on cabotegravir; rilpivirine October 2025(2025)."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:58:38Z","timestamp":1779199118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cpt.70238"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70238","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2025-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}